Danaher SG&A Expenses 2010-2025 | DHR
Danaher annual/quarterly sg&a expenses history and growth rate from 2010 to 2025. Sg&a expenses can be defined as the sum of all selling, general and administrative expenses.
- Danaher sg&a expenses for the quarter ending March 31, 2025 were $1.858B, a 2.82% increase year-over-year.
- Danaher sg&a expenses for the twelve months ending March 31, 2025 were $7.810B, a 6.06% increase year-over-year.
- Danaher annual sg&a expenses for 2024 were $7.759B, a 5.87% increase from 2023.
- Danaher annual sg&a expenses for 2023 were $7.329B, a 2.88% increase from 2022.
- Danaher annual sg&a expenses for 2022 were $7.124B, a 4.5% increase from 2021.
| Danaher Annual SG&A Expenses (Millions of US $) |
|
|---|---|
| 2024 | $7,759 |
| 2023 | $7,329 |
| 2022 | $7,124 |
| 2021 | $6,817 |
| 2020 | $6,896 |
| 2019 | $5,589 |
| 2018 | $5,391 |
| 2017 | $5,043 |
| 2016 | $5,624 |
| 2015 | $4,748 |
| 2014 | $4,035 |
| 2013 | $5,117 |
| 2012 | $5,181 |
| 2011 | $4,608 |
| 2010 | $3,604 |
| 2009 | $3,115 |
| Danaher Quarterly SG&A Expenses (Millions of US $) |
|
|---|---|
| 2025-03-31 | $1,858 |
| 2024-12-31 | $2,023 |
| 2024-09-30 | $2,060 |
| 2024-06-30 | $1,869 |
| 2024-03-31 | $1,807 |
| 2023-12-31 | $2,035 |
| 2023-09-30 | $1,728 |
| 2023-06-30 | $1,794 |
| 2023-03-31 | $1,772 |
| 2022-12-31 | $798 |
| 2022-09-30 | $2,149 |
| 2022-06-30 | $2,085 |
| 2022-03-31 | $2,092 |
| 2021-12-31 | $913 |
| 2021-09-30 | $2,062 |
| 2021-06-30 | $1,966 |
| 2021-03-31 | $1,876 |
| 2020-12-31 | $1,957 |
| 2020-09-30 | $1,796 |
| 2020-06-30 | $1,685 |
| 2020-03-31 | $1,458 |
| 2019-12-31 | $1,449 |
| 2019-09-30 | $1,383 |
| 2019-06-30 | $1,390 |
| 2019-03-31 | $1,368 |
| 2018-12-31 | $593 |
| 2018-09-30 | $1,559 |
| 2018-06-30 | $1,638 |
| 2018-03-31 | $1,602 |
| 2017-12-31 | $572 |
| 2017-09-30 | $1,498 |
| 2017-06-30 | $1,522 |
| 2017-03-31 | $1,450 |
| 2016-12-31 | $1,519 |
| 2016-09-30 | $1,346 |
| 2016-06-30 | $1,431 |
| 2016-03-31 | $1,328 |
| 2015-12-31 | $728 |
| 2015-09-30 | $1,201 |
| 2015-06-30 | $1,405 |
| 2015-03-31 | $1,414 |
| 2014-12-31 | $1,580 |
| 2014-09-30 | $1,298 |
| 2014-06-30 | $1,395 |
| 2014-03-31 | $1,351 |
| 2013-12-31 | $1,492 |
| 2013-09-30 | $1,303 |
| 2013-06-30 | $1,340 |
| 2013-03-31 | $1,298 |
| 2012-12-31 | $1,407 |
| 2012-09-30 | $1,251 |
| 2012-06-30 | $1,279 |
| 2012-03-31 | $1,245 |
| 2011-12-31 | $1,288 |
| 2011-09-30 | $1,268 |
| 2011-06-30 | $1,088 |
| 2011-03-31 | $963 |
| 2010-12-31 | $968 |
| 2010-09-30 | $873 |
| 2010-06-30 | $897 |
| 2010-03-31 | $866 |
| 2009-12-31 | $816 |
| 2009-09-30 | $782 |
| 2009-06-30 | $760 |
| 2009-03-31 | $757 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Services | $140.515B | $23.875B |
| Danaher Corporation is a global conglomerate that designs, manufactures and markets diverse lines of professional, industrial, commercial and consumer products. The company's segmental details are provided below: Life Sciences segment offers a broad range of research tools used to analyze a range of critical areas including genes, proteins, metabolites and cells to understand the causes of diseases, identify new therapies, and test new drugs and vaccines. Range of industries served includes biopharmaceutical, food and beverage, medical, aerospace, microelectronics, and general industrial. Diagnostics segment offers analytical instruments, reagents, consumables, software and services that are deployed in reference laboratories, hospitals, physicians' offices and other critical care settings. It helps to diagnose diseases and take suitable treatment decisions. Environmental & Applied Solutions segment offers products and services that help keep food and water supplies safe globally. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CVS Health (CVS) | United States | $84.516B | 10.51 |
| Elevance Health (ELV) | United States | $84.143B | 10.86 |
| Cencora (COR) | United States | $56.815B | 19.77 |
| Natera (NTRA) | United States | $23.263B | 0.00 |
| DiDi Global (DIDIY) | China | $22.732B | 24.15 |
| Labcorp Holdings (LH) | United States | $21.849B | 17.72 |
| BioMerieux (BMXMF) | France | $16.861B | 0.00 |
| EUROFINS SCIENT (ERFSF) | Luxembourg | $13.354B | 0.00 |
| CochLear (CHEOY) | Australia | $12.742B | 0.00 |
| Solventum (SOLV) | United States | $12.673B | 13.42 |
| ICON (ICLR) | Ireland | $11.895B | 11.06 |
| Revvity (RVTY) | United States | $11.192B | 19.26 |
| Viatris (VTRS) | United States | $10.387B | 3.57 |
| Avantor (AVTR) | United States | $9.152B | 13.30 |
| Medpace Holdings (MEDP) | United States | $8.871B | 23.56 |
| HealthEquity (HQY) | United States | $8.752B | 38.34 |
| Sonic Healthcare (SKHHY) | Australia | $8.201B | 0.00 |
| Charles River Laboratories (CRL) | United States | $7.239B | 14.19 |
| Amplifon S.p.A (AMFPF) | Italy | $5.378B | 29.44 |
| Bausch + Lomb (BLCO) | Canada | $4.245B | 25.00 |
| BrightSpring Health Services (BTSG) | United States | $4.003B | 36.73 |
| Sotera Health (SHC) | United States | $3.148B | 17.89 |
| Alignment Healthcare (ALHC) | United States | $2.764B | 0.00 |
| Concentras Parent (CON) | United States | $2.689B | 15.54 |
| Surgery Partners (SGRY) | United States | $2.589B | 33.67 |
| Organon (OGN) | United States | $2.548B | 2.71 |
| GeneDx Holdings (WGS) | United States | $2.274B | 87.59 |
| PACS (PACS) | United States | $1.943B | 0.00 |
| Ardent Health (ARDT) | United States | $1.851B | 7.89 |
| Premier (PINC) | United States | $1.802B | 13.68 |
| Progyny (PGNY) | United States | $1.782B | 39.23 |
| GoodRx Holdings (GDRX) | United States | $1.675B | 33.50 |
| Teladoc Health (TDOC) | United States | $1.384B | 0.00 |
| Pediatrix Medical (MD) | United States | $1.149B | 8.74 |
| Establishment Labs Holdings (ESTA) | $1.058B | 0.00 | |
| CareDx (CDNA) | United States | $1.055B | 16.48 |
| Ryman Healthcare (RYHTY) | New Zealand | $0.999B | 0.00 |
| Agilon Health (AGL) | United States | $0.890B | 0.00 |
| AMN Healthcare Services Inc (AMN) | United States | $0.811B | 7.59 |
| QDM (QDMI) | Hong Kong, SAR China | $0.729B | 0.00 |
| LifeMD (LFMD) | United States | $0.650B | 0.00 |
| Nutex Health (NUTX) | United States | $0.649B | 9.83 |
| Embecta (EMBC) | United States | $0.574B | 3.87 |
| InnovAge Holding (INNV) | United States | $0.536B | 0.00 |
| Enhabit (EHAB) | United States | $0.470B | 38.67 |
| Auna S.A (AUNA) | Luxembourg | $0.463B | 10.42 |
| Sonida Senior Living (SNDA) | United States | $0.457B | 0.00 |
| SBC Medicals (SBC) | United States | $0.450B | 0.00 |
| Omada Health (OMDA) | $0.382B | 0.00 | |
| Performant Healthcare (PHLT) | United States | $0.281B | 0.00 |
| Beauty Health (SKIN) | United States | $0.243B | 0.00 |
| COMPASS Pathways (CMPS) | United Kingdom | $0.220B | 0.00 |
| Oncology Institute (TOI) | United States | $0.204B | 0.00 |
| DocGo (DCGO) | United States | $0.172B | 28.17 |
| So-Young (SY) | China | $0.168B | 0.00 |
| Pheton Holdings (PTHL) | China | $0.130B | 0.00 |
| OncoCyte (IMDX) | United States | $0.105B | 0.00 |
| KindlyMD (NAKA) | United States | $0.098B | 0.00 |
| Sera Prognostics (SERA) | United States | $0.070B | 0.00 |
| NeueHealth (NEUE) | United States | $0.061B | 0.00 |
| Ascend Wellness Holdings (AAWH) | United States | $0.059B | 0.00 |
| IceCure Medical (ICCM) | Israel | $0.051B | 0.00 |
| ModivCare (MODV) | United States | $0.049B | 0.00 |
| Basel Medical Group (BMGL) | Singapore | $0.044B | 0.00 |
| Biodesix (BDSX) | United States | $0.039B | 0.00 |
| NeuroOne Medical Technologies (NMTC) | United States | $0.033B | 0.00 |
| Intelligent Bio Solutions (INBS) | United States | $0.013B | 0.00 |
| Co-Diagnostics (CODX) | United States | $0.009B | 0.00 |
| XWELL (XWEL) | United States | $0.005B | 0.00 |
| BioNexus Gene Lab (BGLC) | $0.005B | 0.00 | |
| Aclarion (ACON) | United States | $0.004B | 0.00 |
| SeaStar Medical Holding (ICU) | United States | $0.004B | 0.00 |
| INVO Fertility (IVF) | United States | $0.002B | 0.00 |
| ISpecimen (ISPC) | United States | $0.002B | 0.00 |
| NewGenIvf Group (NIVF) | Thailand | $0.001B | 0.00 |
| Cano Health (CANOQ) | United States | $0.000B | 0.00 |